Skip to content
Preprint via OpenAlex

Faculty Opinions recommendation of Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.

Björn Schumacher

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2019

Abstract

Background: Cellular senescence(definition) is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans.Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescenceassociated disease.Selectively ablating senescent cells using dasatinib plus quercetin (DQ) alleviates IPF-related dysfunction in bleomycin-administered mice.Methods: A two-center, open-label study of intermittent DQ (D:100 mg/day, Q:1250 mg/day, three-days/week over three-weeks) was conducted in participants with IPF (n = 14) to evaluate feasibility of implementing a senolytic intervention.The primary endpoints were retention rates and completion rates for planned clinical assessments.Secondary endpoints were safety and change in functional and reported health measures.Associations with the senescence-associated secretory phenotype (SASP) were explored.Findings: Fourteen patients with stable IPF were recruited.The retention rate was 100% with no DQ discontinuation; planned clinical assessments were complete in 13/14 participants.One serious adverse event was reported.Non-serious events were primarily mild-moderate, with respiratory symptoms (n = 16 total events), skin irritation/bruising (n = 14), and gastrointestinal discomfort (n = 12) being most frequent.Physical function evaluated as 6-min walk distance, 4-m gait speed, and chair-stands time was significantly and clinicallymeaningfully improved (p b .05).Pulmonary function, clinical chemistries, frailty index (FI-LAB), and reported health were unchanged.DQ effects on circulat.ingSASP factors were inconclusive, but correlations were observed between change in function and change in SASP-related matrix-remodeling proteins, microRNAs, and proinflammatory cytokines (23/48 markers r ≥ 0.50).Interpretation: Our first-in-humans open-label pilot supports study feasibility and provides initial evidence that senolytics(definition) may alleviate physical dysfunction in IPF, warranting evaluation of DQ in larger randomized controlled trials for senescence-related diseases.ClinicalTrials.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3410/f.734825206.793563347
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Schumacher, B. (2019). Faculty Opinions recommendation of Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. <em>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature</em>. https://doi.org/10.3410/f.734825206.793563347
Vancouver
Schumacher B. Faculty Opinions recommendation of Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. 2019. doi:10.3410/f.734825206.793563347.
BibTeX
@unpublished{bjrn2019Facult, title = {Faculty Opinions recommendation of Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.}, author = {Björn Schumacher}, journal = {Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature}, year = {2019}, doi = {10.3410/f.734825206.793563347}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings